Vestcor Inc Purchases 174,644 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Vestcor Inc increased its stake in Bristol Myers Squibb by 75.7%, purchasing an additional 174,644 shares to hold 405,330 shares valued at about $18.28 million at the end of the quarter.
• Other large institutional moves include Norges Bank opening a roughly $1.55 billion position and Charles Schwab raising its holdings to 70.8 million shares, leaving about 76.41% of the stock owned by hedge funds and institutions.
• BMS reported quarterly EPS of $1.26, missing estimates though revenue rose slightly, and set FY2026 guidance of 6.050–6.350 EPS; the company also announced a $0.63 quarterly dividend (a 4.2% yield) while analysts maintain a consensus "Hold" rating with a $61 average price target.

Vestcor Inc grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 75.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 405,330 shares of the biopharmaceutical company's stock after purchasing an additional 174,644 shares during the period. Vestcor Inc's holdings in Bristol Myers Squibb were worth $18,280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,554,154,000. Charles Schwab Investment Management Inc. grew its position in Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company's stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company's stock worth $523,599,000 after acquiring an additional 9,171,098 shares in the last quarter. Man Group plc lifted its holdings in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after acquiring an additional 5,503,391 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Bristol Myers Squibb by 142.8% during the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company's stock valued at $390,541,000 after purchasing an additional 4,961,869 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Guggenheim reissued a "buy" rating and issued a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research note on Tuesday, January 13th. Scotiabank restated a "sector perform" rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. UBS Group reiterated a "buy" rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a research report on Friday. Finally, Piper Sandler restated an "overweight" rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $61.00.

Bristol Myers Squibb Trading Down 0.9%

NYSE BMY opened at $60.21 on Monday. The stock has a market cap of $122.62 billion, a P/E ratio of 17.45, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a 50 day simple moving average of $57.66 and a two-hundred day simple moving average of $51.03. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb's quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb's dividend payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.